viernes, 28 de julio de 2023

FDA shows generic lamotrigine extended-release tablets are bioequivalent to innovator drug in fully replicated crossover bioequivalence study

https://www.fda.gov/drugs/regulatory-science-action/fda-shows-generic-lamotrigine-extended-release-tablets-are-bioequivalent-innovator-drug-fully?utm_medium=email&utm_source=govdelivery

No hay comentarios:

Publicar un comentario